Based on the FLAURA trial, would you consider using osimertinib firstline in EGFR-mutated NSCLC?
Community PollStarted
What is your preferred first line treatment for EGFR-mutated NSCLC?
27 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Henry Ford Cancer Institute/Henry Ford Hospital
Answered on
Yes I would. The primary reasons are that the drug is not only has better PFS but also is better tolerated and has CNS activity. There remain several questions,
1. What therapy to choose in patients who progress after front line osimertinib?
2. Does the drug only work in the 50-60% of the patients w...
Join for free or sign in to see the full answer